Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.

IF 5.1 2区医学 Q1 HEMATOLOGY British Journal of Haematology Pub Date : 2024-08-27 DOI:10.1111/bjh.19700

Othman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, Mark Forsberg, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Tanvi Patel, Asis Shrestha, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Mansi R Shah, Aishee Bag, Anita D'Souza, Carolina Schinke, Rajshekhar Chakraborty, Nishi Shah, Meera Mohan

{"title":"Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.","authors":"Othman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, Mark Forsberg, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Tanvi Patel, Asis Shrestha, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Mansi R Shah, Aishee Bag, Anita D'Souza, Carolina Schinke, Rajshekhar Chakraborty, Nishi Shah, Meera Mohan","doi":"10.1111/bjh.19700","DOIUrl":null,"url":null,"abstract":"<p><p>The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the association of baseline GPS and CAR-HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high-risk CAR-HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bjh.19700","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Glasgow prognostic score (GPS) and CAR-HEMATOTOX (CAR-HT) score identify multiple myeloma (MM) patients at high risk for immune-mediated toxicity and early mortality with cellular immunotherapy. However, their association with outcomes in patients receiving T-cell redirecting bispecific antibodies (bsAb) is unclear. This multi-centre retrospective study examines the association of baseline GPS and CAR-HT scores with outcomes in 126 MM patients treated with bsAb. Overall, 19% were identified as GPS high risk but did not experience increased toxicity or mortality. Conversely, high-risk CAR-HT patients had a higher incidence of infections and inferior survival, suggesting a need for aggressive infection mitigation strategies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫预后评分可预测接受双特异性抗体治疗的复发性多发性骨髓瘤患者的感染风险和生存结果。

格拉斯哥预后评分（GPS）和CAR-HEMATOTOX（CAR-HT）评分可确定多发性骨髓瘤（MM）患者在接受细胞免疫疗法后发生免疫介导毒性和早期死亡的高风险。然而，它们与接受T细胞重定向双特异性抗体（bsAb）治疗患者的预后之间的关系尚不清楚。这项多中心回顾性研究考察了126名接受双特异性抗体治疗的MM患者的基线GPS和CAR-HT评分与预后的关系。总体而言，19% 的患者被确定为 GPS 高风险，但毒性或死亡率并未增加。相反，高风险CAR-HT患者的感染发生率较高，存活率较低，这表明需要采取积极的感染缓解策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.